Rosalind Advisors’s Viridian Therapeutics VRDN Stock Holding History

Rosalind Advisors’s Portfolio VRDN Stock Details VRDN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-250,401	Closed	-$4.9M	–	44
2026 Q1	$4.9M	Sell	250,401 -199,599	-44%	-$5.93M	1.97%	18
2025 Q4	$14M	Sell	450,000 -150,000	-25%	-$4.11M	4.92%	5
2025 Q3	$12.9M	Sell	600,000 -100,000	-14%	-$1.8M	4.43%	9
2025 Q2	$9.79M	Buy	700,000 +105,000	+18%	+$1.43M	4.64%	7
2025 Q1	$8.02M	Buy	+595,000	New	+$10.1M	3.9%	11
2024 Q3	–	Sell	-300,000	Closed	-$3.9M	–	41
2024 Q2	$3.9M	Hold	300,000	–	–	3%	16
2024 Q1	$5.25M	Sell	300,000 -60,332	-17%	-$1.17M	4.91%	9
2023 Q4	$7.85M	Buy	+360,332	New	+$5.69M	6.46%	5

Other funds holding VRDN

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return

PBA

Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

FFM

Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Rosalind Advisors's VRDN Position: Q2 2026 in Review

Rosalind Advisors sold out of Viridian Therapeutics (VRDN) in Q2 2026, closing a stake of 250,401 shares — an estimated $4.9M sold.

Rosalind Advisors first reported a position in VRDN in Q4 2023 and held it in 8 quarters. The position peaked at $14M in Q4 2025. 214 funds tracked by Wall St. Rank hold VRDN as of Q2 2026.

Rosalind Advisors reported no remaining Viridian Therapeutics position as of Q2 2026 after selling out during the quarter.
Rosalind Advisors sold 250,401 Viridian Therapeutics shares in Q2 2026, an estimated $4.9M.
Rosalind Advisors first reported a position in Viridian Therapeutics in Q4 2023 and held it in 8 quarters.
Rosalind Advisors's Viridian Therapeutics position peaked at $14M in Q4 2025.
214 funds tracked by Wall St. Rank held Viridian Therapeutics as of Q2 2026.

Based on Rosalind Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.